Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C2L-OCT-01 PR Extension in Acromegaly
NCT00635765Phase 3Completed
- Sponsor
- Ambrilia Biopharma Inc.
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 3 trial of Octreotide long-acting injection in acromegaly, sponsored by Ambrilia Biopharma Inc.. Started Oct 2007; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00635765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635765.